ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 910

Survival Benefit of Statin Use in Ankylosing Spondylitis and Psoriatic Arthritis: A General Population-Based Cohort Study

Amar Oza1, Na Lu2 and Hyon K. Choi3, 1Allergy, Immunology, and Rheumatology, Massachusetts General Hospital, Boston, MA, 2Clinical Epidemiology, Boston University School of Medicine, Boston, MA, 3Rheumatology, Allergy and Immunology, Massachusetts General Hospital and Harvard Medical School, Boston, MA

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Ankylosing spondylitis (AS), Cardiovascular disease, morbidity and mortality, psoriatic arthritis and statins

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2016

Title: Plenary Session I: Discovery 2016

Session Type: ACR Plenary Session

Session Time: 11:00AM-12:30PM

Background/Purpose: Recent studies have shown an increase in cardiovascular and all-cause mortality in ankylosing spondylitis (AS) and psoriatic arthritis (PsA).1 The hypothesized dual role of statins in both lowering lipids and reducing inflammation may thus lead to survival benefits in patients with these seronegative spondyloarthropathies. We examined the potential survival benefit of statin use in AS and PsA within a general population context.

Methods: We performed an incident user cohort study with time-stratified propensity score matching using a UK general population database. The population studied included patients with AS or PsA between January 1, 2000 and December 31, 2014. To account for potential confounders, we compared propensity score-matched cohorts of statin initiators and comparators (non-initiators) within 1-year cohort accrual blocks. 50 variables were used to create propensity scores, including but not limited to the disease duration, socio-economic status, BMI, lifestyle factors, and medication use.

Results: 2,904 patients with AS or PsA who initiated statins compared to 2,904 propensity matched-comparators with AS or PsA that were not started on statins. 271 died during the follow up (mean = 5.3 years), whereas among the propensity-matched non-initiators, 376 patients died during the follow up (mean = 5.15 years) (Figure 1). This corresponds to incidence rates of 17.62/1000 and 25.14/1000 person-years (PY), respectively. The baseline characteristics were well balanced in the two groups. Statin initiation was associated with a 33% reduction of all-cause mortality (HR=0.68, 95% CI 0.57-0.81). When we compared the unmatched cohorts to determine the effectiveness of our propensity score matching, the statin initiators (n=3,389) actually showed a 44% higher risk of mortality (HR=1.44, 95% CI 1.22-1.70) than non-initiators (n=3,389 randomly selected) due to confounding by indication (Figure 2).

Conclusion: This general population-based cohort study indicates that statin initiation is associated with a 33% lower risk of mortality for patients with AS or PsA. The magnitude of the inverse association appears to be larger than that observed in population-based cohort studies of patients with rheumatoid arthritis (21%)2 and in meta analyses of randomized trials of the general population (9-14%)3, potentially due to the dual benefits of statin use (i.e. lipid lowering and anti-inflammatory effects) in patients with seronegative spondyloarthropathies. References: 1. Haroon et al. Ann Int Med 2015. 2. Schoenfeld et al. Ann Rheum Dis 2015. 3. Mihaylova et al. Lancet 2012.

   


Disclosure: A. Oza, None; N. Lu, None; H. K. Choi, None.

To cite this abstract in AMA style:

Oza A, Lu N, Choi HK. Survival Benefit of Statin Use in Ankylosing Spondylitis and Psoriatic Arthritis: A General Population-Based Cohort Study [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/survival-benefit-of-statin-use-in-ankylosing-spondylitis-and-psoriatic-arthritis-a-general-population-based-cohort-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/survival-benefit-of-statin-use-in-ankylosing-spondylitis-and-psoriatic-arthritis-a-general-population-based-cohort-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology